HUMATE-P is for intravenous use only. HUMATE-P is available as a lyophilized powder in single-dose vials that contain the labeled amount of VWF:RCo and FVIII activity expressed in IU. The average ratio of VWF:RCo to FVIII is 2.4:1. Do not refrigerate HUMATE-P after reconstitution. Administer within 3 hours after reconstitution.
P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease, Thromb Haemost, № 87, с. 224
Humate-P works by temporarily raising levels of factor VIII or von Willebrand factor in the blood to aid in clotting. Humate-P is a combination medicine used to treat or prevent bleeding episodes in people with von Willebrand disease. Humate-P is also used to treat or prevent bleeding episodes in people with hemophilia A.
Additionally, each vial of Humate-P also contains vWF:RCof activity in IU for the treatment of VWD. Recommended Dose and Dosage Adjustment. Therapy For
Package Insert - Humate-P; Supporting Documents. Supporting Documents older than three years - Humate-P; Content current as of: . Approved Blood Products
HUMATE-P package: HUMATE-P vial, diluent vial, Mix2Vial 1. Preparation 3. Remove packaging 5. Unscrew diluent vial 2. Connect diluent vial 4. Connect HUMATE-P vial 6. Withdraw mixed solution HUMATE-P Key Information INSTRUCTIONS FOR USE For demonstration purposes, the vials are colour-coded as Prepare using aseptic technique
Administer a dose of IU VWF:RCo/kg body weight. Maintenance Doses The initial maintenance dose of Humate-P for the prevention of excessive bleeding
Humate-P has a higher Factor potency than cryoprecipitate preparations. Each vial of Humate-P contains the labeled amount of Factor VIII activity in international units. Additionally, each vial of Humate-P also contains the labeled amount of von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) activity expressed in IU (see DOSAGE AND
P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand Disease
Comments